BioAxone BioSciences receives NIH grant for cerebral cavernous malformation treatment: 5 points

Spine

The National Institutes of Health and the National Institute of Neurological Disorders and Stroke gave Cambridge, Mass.-based BioAxone BioSciences a grant for the development of its molecule kinase inhibitor, BA-1049.

Here are five points:

 

1. The Phase I/Phase II grant totals $3.2 million.

 

2. BA-1049 is intended to treat cerebral cavernous malformations.

 

3. The terms of the grant allow BioAxone to partner with University of Chicago, Durham, N.C.-based Duke University and the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center.

 

4. CCM mutation results in benign endothelial cell tumors, causing headaches, seizures and neurological complications.

 

5. The researchers will complete proof of concept studies to test the effectiveness of BA-1049 with human vascular tissue and transgenic mice expressing defective copies of the CCM gene.

 

"We are delighted that this grant has allowed us to form a strong consortium of industry and academic partners to develop the first effective drug to treat this disorder," said Lisa McKerracher, PhD, CEO, BioAxone.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers